At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 68 enrolled
Drug / intervention
MLN0128 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open Label, Dose Escalation Study of Oral Administration of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
In Brief
A Phase 1 clinical trial evaluating MLN0128, paclitaxel, and 1 other intervention for Advanced Solid Malignancies and Hematologic Malignancies. Completed, enrolled 68 participants across 3 sites.
Detailed Summary
This is a Phase I, open label, dose escalation study of oral administration of MLN0128 in combination with paclitaxel, with/without trastuzumab, in participants with advanced solid malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
First PostedMay 2011
Primary CompletionSep 2017
TodayJul 2026
First PostedMay 10, 2011
Enrollment StartFeb 28, 2011
Primary CompletionSep 15, 2017
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 15.1 years ago
Interventions
MLN0128drug
MLN0128 capsules
paclitaxeldrug
paclitaxel intravenous infusion
trastuzumabdrug
trastuzumab intravenous infusion